This article was originally published in The Tan Sheet
Private labeler receives FDA clearance for acetaminophen, aspirin and caffeine tablets (ANDA 75-794) July 12. Product is first approved generic version of Bristol-Myers Squibb's Excedrin Migraine, which lost marketing exclusivity Jan. 14. Perrigo says it will not launch store brand equivalent until Spring 2002, however, as it focuses on shipping products planned before quality control problems hampered launches last year (1see item, p. 5)
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.